Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study

Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study

In this small pilot sub-study, longitudinal gut microbiota composition changes, after successful treatment of hepatitis C virus (HCV) with the co-formulated glecaprevir/pibrentasvir (GLE/PIB), were analyzed before treatment (baseline) and 12 weeks post-treatment. Participating patients provided a fr...

Full description

Bibliographic Details
Main Authors: Bahtiyar Yilmaz, Lisa Ruckstuhl, Beat Müllhaupt, Lorenzo Magenta, Melanie Harrer Kuster, Olivier Clerc, Ralph Torgler, Nasser Semmo
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Pharmaceuticals
Subjects:
HCV
gut microbiota
alpha-diversity
beta-diversity
direct-acting antivirals
Online Access:https://www.mdpi.com/1424-8247/14/9/931

Internet

https://www.mdpi.com/1424-8247/14/9/931

Similar Items